The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | First-in-human study of the oral CLK inhibitor BH-30236 in adults with R/R AML or HR-MDS
Eytan Stein, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the first-in-human study (NCT06501196) investigating the oral CDC-like kinase (CLK) inhibitor BH-30236 as monotherapy or in combination with venetoclax in adults with relapsed/refractory (R/R) acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (HR-MDS). Dr Stein highlights that BH-30236 monotherapy is well tolerated and reduces blast counts, while combining the agent with venetoclax has led to notable responses and complete remissions, even in patients previously exposed to venetoclax. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So this is a really exciting trial. It’s with a CLK inhibitor, which are a class of compounds that may have preferential activity, although we don’t know yet, and patients with splicing factor mutant acute myeloid leukemia and high-risk myelodysplastic syndromes. What we’ve seen in the trial today and what we’re presenting in a poster is that monotherapy with this agent is well tolerated...
So this is a really exciting trial. It’s with a CLK inhibitor, which are a class of compounds that may have preferential activity, although we don’t know yet, and patients with splicing factor mutant acute myeloid leukemia and high-risk myelodysplastic syndromes. What we’ve seen in the trial today and what we’re presenting in a poster is that monotherapy with this agent is well tolerated. We’ve seen some diarrhea, but it’s been manageable. We have seen some blast reductions with monotherapy. But then when you give the drug in combination with venetoclax, even in patients who’ve previously been exposed to venetoclax, we’re seeing some real responses and some real complete remissions. So we’re very excited about this data, excited to expand out the trial and treat more patients, see how many more responses we can get.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
